Press Releases

Interim results for the six months ended 31 January 2019

C4X Discovery Holdings plc

("C4XD" or the "Company")

Interim results for the six months ended 31 January 2019

30 April 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces its interim results for the six months ended 31 January 2019.

Operational highlights:

Partnering updates

  • Partnering process for oral NRF-2 activator programme launched
    • Commercial interest across multiple disease areas including, Chronic Obstructive Pulmonary Disease (“COPD”), Pulmonary Arterial Hypertension (“PAH”) and Sickle Cell Disease (“SCD”)
  • Indivior continues to progress C4X_3256 (Orexin-1 receptor antagonist)
    • NIH funded investigation of the effect of C4X_3256 in cocaine addiction efficacy models showing promising results with continued partner support

Discovery portfolio growth

  • Expansion of proprietary drug discovery portfolio continues
    • Portfolio contains eleven active discovery programmes, up from nine in 2018
      • Includes three late-stage programmes demonstrating in vivo activity
    • Significant expansion of early-stage discovery portfolio and capabilities during the period:
      • Two drug discovery partnerships announced, adding new programmes to the portfolio:
        • LifeArc®: to generate lead compounds on an inflammation/oncology drug target subject of multiple pre-clinical deals in the last 12 months
        • GTN Ltd (“GTN”): to identify potential small molecule hits against a neurodegeneration target
      • Exclusive target discovery partnership with Horizon Discovery Group plc (AIM: HZD, “Horizon”) to validate novel, synthetic lethal oncology targets to initiate drug discovery programmes against
    • Continued development of protocol and capabilities to prosecute Taxonomy3® outputs with the aim of establishing a portfolio of targets suitable for multi-asset and single asset deals

Proprietary technology and commercialisation capability development

  • Prudent investment in expansion of drug discovery capabilities continues
    • Launch of Stage 2 of 4Sight, C4XD’s proprietary molecular visualisation and design tool, in collaboration with Epic Games
  • Expansion of commercial-focussed resource


  • Successful fundraise of £10.1 million (before expenses) completed 9th October 2018, with a total of 11,210,674 shares issued to both new and existing investors

Financial highlights:

  • R&D investment was £4.9 million in the six months ending 31 January 2019, up £1.5 million from the £3.4 million in the six months ended 31 January 2018, reflecting progress across the portfolio
  • Cash, cash equivalents, short-term investments and deposits at 31 January 2019 of £9.2 million (31 July 2018: £5.6 million and 31 January 2018: £1.4 million)
  • Net assets at 31 January 2019 of £12.8 million (31 July 2018: £8.2 million and 31 January 2018: £5.5 million)

Dr Clive Dix, CEO of C4X Discovery, said: “C4XD has continued to strengthen its drug discovery capabilities and advance its portfolio of novel pre-clinical assets this first half year. Having launched a partnering process for our NRF-2 programme, we are now in licensing discussions with pharmaceutical partners to take forward our lead series to clinical development. We are also excited to enter new partnerships with LifeArc, GTN, and Horizon which have enabled us to augment our discovery engine with technologies at the cutting-edge of drug discovery and accelerate the growth of our portfolio by accessing highly attractive earlier-stage therapeutic targets and chemistry. I would like to take this opportunity to thank our shareholders for their support and we look forward to continued success in the second half of the year.”